Citius Oncology Inc. (CTOR)
Citius Oncology Inc. (CTOR) Stock Price, Analysis & Data
| Bid | 0.54 |
| Market Cap | 68.81M |
| Revenue (ttm) | 5.61M |
| Net Income (ttm) | -42.51M |
| Beta | 3.49 |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 1.95 |
| P/S (ttm) | 12.26 |
| Earnings Date | n/a |
| Ask | 0.98 |
| Volume | 274,784 |
| Avg. Volume (20D) | 81,712 |
| Open | 0.77 |
| Previous Close | 0.92 |
| Day's Range | 0.70 - 0.78 |
| 52-Week Range | 0.49 - 2.25 |
| Analyst | Buy |
| Price Target | 4 (440.54%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....
Full Company ProfileFinancial Performance
In 2025, Citius Oncology's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -24.76M, an increase of 17.08%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CTOR stock is "Buy". The 12-month stock price forecast is 4, which is upside of 440.54% from the latest price.
Stock ForecastsEarnings Surprise
3 months ago · Pharmaceutical Technology
Citius raises $36.5m for Lymphir commercialisationThe capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.
